BCM
LLY icon

BluePath Capital Management’s Eli Lilly LLY Stock Holding History

BluePath Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,580
Closed -$1.26M – 100
2024
Q4 		$1.26M Buy
1,580
+999
+172% +$827K 0.68% 32
2024
Q3 		$515K Buy
581
+2
+0.3% +$1.8K 0.32% 77
2024
Q2 		$524K Sell
579
-28
-5% -$22.4K 0.37% 78
2024
Q1 		$472K Sell
607
-141
-19% -$100K 0.36% 75
2023
Q4 		$471K Buy
748
+33
+5% +$19.3K 0.4% 58
2023
Q3 		$384K Buy
+715
New +$368K 0.35% 58

Other funds holding LLY

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BluePath Capital Management's LLY Position: Q1 2025 in Review

BluePath Capital Management sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 1,580 shares — an estimated $1.26M sold.

BluePath Capital Management first reported a position in LLY in Q3 2023 and held it in 6 quarters. The position peaked at $1.26M in Q4 2024. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

  • BluePath Capital Management reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
  • BluePath Capital Management sold 1,580 Eli Lilly shares in Q1 2025, an estimated $1.26M.
  • BluePath Capital Management first reported a position in Eli Lilly in Q3 2023 and held it in 6 quarters.
  • BluePath Capital Management's Eli Lilly position peaked at $1.26M in Q4 2024.
  • 3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on BluePath Capital Management's 13F filing for Q1 2025, filed 6 May 2025.